Novel curcumin analogs, GO-Y030 and GO-Y078, are multitargeted agents with enhanced abilities for multiple myeloma

Chieko Kudo, Hiroyuki Yamakoshi, Atsuko Sato, Hisatsugu Ohori, Chikashi Ishioka, Yoshiharu Iwabuchi, Hiroyuki Shibata

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

Background: Multiple myeloma remains an incurable malignancy despite of the recent approval of new molecular-targeted agents. The complex molecular mechanism, composed of various signal networks, including nuclear factor-κB (NF-κB), phosphoinositide 3-kinase (PBK)I/KT, Janus kinase (JAK)lsignal transducer and activator of transcription 3 (STAT3), and interferon regulatory factor 4 (1RF4) pathways, is a major reason for treatment failure. Curcumin can regulate these molecules, but its low bioavailability prevents its clinical application. Materials and Methods: Growth-suppressive abilities of newly synthesized analogs, GO-Y030 and GO-Y078 were analyzed. Molecular-targeted abilities of the analogs for NF-κB, PI3K/AKT, JAK/STAT3, IRF4 pathways, as well as inhibition of interleukin-6 (IL-6) production, were also examined. Results: GO-Y030 and GO-Y078 were 7 to 12-fold more potent growth suppressors for myeloma cells, and 6- to 15-fold stronger inhibitors of NF-κB, PI3K/AKT, JAK/STAT3, and IRF4 pathways than curcumin. GO-Y78 also 14-fold more potently inhibited IL-6 production. Conclusion: GO-Y030 and GO-Y078 are potential therapeutic candidates with enhanced abilities for multiple myeloma.

Original languageEnglish
Pages (from-to)3719-3726
Number of pages8
JournalAnticancer research
Volume31
Issue number11
Publication statusPublished - 2011 Nov 1

Keywords

  • Curcumin analog
  • IRF4
  • JAK/STAT3
  • Multiple myeloma
  • NF-κB
  • PI3K/AKT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel curcumin analogs, GO-Y030 and GO-Y078, are multitargeted agents with enhanced abilities for multiple myeloma'. Together they form a unique fingerprint.

Cite this